secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-116023
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo closes $32.3M financing and licenses NASH/obesity drugs from Dong-A
---------------------------------------------------------------------------

- Public offering grossed ~$17.3M (full over-allotment); private placement $15M from Dong-A; net proceeds ~$15.1M.
- Exclusive license for DA-1241 (NASH) and DA-1726 (obesity/T2D); NeuroBo holds global rights ex-Asia Pacific.
- Issued 3.1M common shares, 2.6M Series B preferred shares, and warrants for up to 11.5M common shares.
- Warrants exercisable at $3.00 after stockholder approval; meeting expected by Dec 22, 2022.
- Preferred stock has no dividend rights, no liquidation preference, and limited voting rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer